Satsuma Prescription drugs, Inc. (NASDAQ:STSA – Get Ranking) was the recipient of a giant improve briefly curiosity in October. As of October fifteenth, there was quick curiosity totalling 462,800 shares, a rise of 15.0% from the September thirtieth whole of 402,300 shares. Based mostly on a median buying and selling quantity of 124,800 shares, the short-interest ratio is at present 3.7 days. Roughly 2.1% of the corporate’s inventory are bought quick.
Wall Road Analyst Weigh In
A number of analysis analysts have weighed in on the corporate. Jonestrading assumed protection on Satsuma Prescription drugs in a analysis report on Wednesday, August twenty fourth. They issued a “purchase” ranking and a $14.00 goal value on the inventory. HC Wainwright upped their goal value on Satsuma Prescription drugs from $15.00 to $18.00 and gave the inventory a “purchase” ranking in a analysis report on Wednesday, September twenty first. SVB Leerink raised Satsuma Prescription drugs from a “market carry out” ranking to an “outperform” ranking and upped their goal value for the inventory from $5.00 to $15.00 in a analysis report on Monday, October tenth. Lastly, LADENBURG THALM/SH SH assumed protection on Satsuma Prescription drugs in a analysis report on Wednesday, August thirty first. They issued a “purchase” ranking and a $16.00 goal value on the inventory. 5 analysts have rated the inventory with a purchase ranking, In keeping with MarketBeat.com, the inventory at present has a consensus ranking of “Purchase” and a consensus goal value of $15.20.
Institutional Inflows and Outflows
Hedge funds have not too long ago made adjustments to their positions within the inventory. UBS Group AG boosted its stake in Satsuma Prescription drugs by 613.2% throughout the 2nd quarter. UBS Group AG now owns 17,594 shares of the monetary providers supplier’s inventory valued at $73,000 after buying a further 15,127 shares throughout the interval. State Road Corp boosted its stake in Satsuma Prescription drugs by 20.0% throughout the 1st quarter. State Road Corp now owns 43,036 shares of the monetary providers supplier’s inventory valued at $164,000 after buying a further 7,176 shares throughout the interval. JPMorgan Chase & Co. purchased a brand new stake in Satsuma Prescription drugs throughout the 2nd quarter valued at roughly $195,000. Dimensional Fund Advisors LP boosted its stake in Satsuma Prescription drugs by 8.5% throughout the 1st quarter. Dimensional Fund Advisors LP now owns 219,864 shares of the monetary providers supplier’s inventory valued at $835,000 after buying a further 17,180 shares throughout the interval. Lastly, Walleye Capital LLC purchased a brand new stake in Satsuma Prescription drugs throughout the 1st quarter valued at roughly $995,000. Institutional buyers and hedge funds personal 72.03% of the corporate’s inventory.
Satsuma Prescription drugs Inventory Efficiency
Shares of NASDAQ STSA traded up $0.15 throughout mid-day buying and selling on Friday, reaching $5.06. 118,629 shares of the corporate traded fingers, in comparison with its common quantity of 124,238. The corporate’s fifty day shifting common is $6.16 and its two-hundred day shifting common is $4.77. Satsuma Prescription drugs has a fifty-two week low of $2.51 and a fifty-two week excessive of $8.08.
Satsuma Prescription drugs (NASDAQ:STSA – Get Ranking) final issued its quarterly earnings knowledge on Tuesday, August ninth. The monetary providers supplier reported ($0.52) EPS for the quarter, lacking analysts’ consensus estimates of ($0.48) by ($0.04). As a bunch, equities analysis analysts count on that Satsuma Prescription drugs will put up -1.98 earnings per share for the present fiscal 12 months.
Satsuma Prescription drugs Firm Profile
(Get Ranking)
Satsuma Prescription drugs, Inc, a clinical-stage biopharmaceutical firm, growing novel therapeutic merchandise for the acute remedy of migraines. The corporate’s lead product candidate is STS101, a drug-device mixture of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Part 3 efficacy trials and may be self-administered with proprietary pre-filled, single-use, and nasal supply machine.
Featured Tales
This instantaneous information alert was generated by narrative science expertise and monetary knowledge from MarketBeat as a way to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you contemplate Satsuma Prescription drugs, you will wish to hear this.
MarketBeat retains observe of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Satsuma Prescription drugs wasn’t on the listing.
Whereas Satsuma Prescription drugs at present has a “Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
View The 5 Shares Right here
